MONTREAL, QUEBEC--(Marketwire - June 12, 2008) - MethylGene Inc. (TSX: MYG), today announced the dosing of the first patient in a Phase I clinical trial evaluating MGCD265 in solid tumors (Trial 101). This is the second Phase I trial with the compound which is being evaluated on different dosing schedules.
